# Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/CBIO/gyre-therapeutics-reports-third-quarter-2025-and-year-to-date-financial-results-and-provides-business-update
Ticker: CBIO
Company: Catalyst Biosciences
Source: Catalyst Biosciences
Published: 2025-11-07 11:00 EST
Original Source URL: https://ir.catalystbiosciences.com
## Summary

Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively  Full-year revenue guidance revised to $115-118 million (from $118 - $128 million previously) due to delayed Etorel® (Nintedanib) rollout and government procurement-related uncertainty

## Article Body
Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively  Full-year revenue guidance revised to $115-118 million (from $118 - $128 million previously) due to delayed Etorel® (Nintedanib) rollout and government procurement-related uncertainty
## Recent Company News
- 2026-05-12 20:06 EST — [Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-announces-nmpa-acceptance-of-new-drug-application-for-f351-hydronidone-for-chb-induced-liver-fibrosis-treatment) — Source: Catalyst Biosciences
- 2026-05-07 10:00 EST — [Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-reports-first-quarter-2026-results-and-provides-business-update) — Source: Catalyst Biosciences
- 2026-03-17 11:00 EST — [Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-announces-china-s-nmpa-grants-priority-review-to-the-nda-for-hydronidone-f351-for-chb-induced-liver-fibrosis-treatment) — Source: Catalyst Biosciences
- 2026-03-12 10:00 EST — [Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update) — Source: Catalyst Biosciences
- 2026-03-02 13:00 EST — [Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-enters-into-agreement-to-acquire-cullgen-to-gain-targeted-protein-degradation-platform-and-pipeline) — Source: Catalyst Biosciences
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)